Epitalon in Canada: A Research Guide to the Pineal Tetrapeptide

Introduction: why Epitalon Canada searches need a careful guide#

Epitalon Canada searches tend to produce two unsatisfying extremes. On one side are longevity pages that present the tetrapeptide as a near-mythic anti-ageing intervention, often with confident claims about telomere extension, sleep restoration, immune rejuvenation, and lifespan. On the other side are short vendor blurbs that list a sequence, a vial size, and a purity number without explaining where the research claims came from or what their limits are. Neither version is adequate for a Canadian researcher trying to decide whether Epitalon belongs in a serious literature review or a bench protocol.

The compound is genuinely interesting. Epitalon, also spelled Epithalon in much of the older literature, is a synthetic four-amino-acid peptide with the sequence Ala-Glu-Asp-Gly. The abbreviation AEDG is often used interchangeably. Its intellectual history sits mainly in the Russian and Eastern European bioregulator literature associated with Vladimir Khavinson and colleagues, where pineal extracts, short peptide fragments, ageing physiology, melatonin rhythms, and chromatin-level gene regulation were studied for decades. That history is part of why the compound attracts attention. It is also part of why careful interpretation is necessary: the literature base uses methods, endpoints, transliteration conventions, and publication venues that do not always map cleanly onto the way North American researchers evaluate a modern peptide candidate.

This guide is written for research context only. It does not recommend Epitalon for human use, does not provide dosing advice, and does not treat telomere-length claims as a shortcut to clinical anti-ageing. The goal is narrower and more useful: define the molecule, summarise the strongest and weakest parts of the evidence base, explain what a Canadian lab should demand from a supplier, and place Epitalon alongside adjacent longevity compounds without pretending they are interchangeable.

Where the evidence is suggestive, the language here says so. Where the evidence is thin, the guide says that too. The anti-ageing peptide category rewards precision because the commercial incentives reward exaggeration.

What Epitalon is at a molecular level#

Epitalon is a tetrapeptide: alanine, glutamic acid, aspartic acid, and glycine in the fixed sequence Ala-Glu-Asp-Gly. Compared with larger research peptides such as BPC-157, TB-500, CJC-1295, or tirzepatide, it is extremely small. Its molecular weight is approximately 390 Da, which places it closer to a small signalling fragment than to a folded peptide hormone. It has no disulphide bonds, no lipid tail, no drug-affinity-complex extension, and no obvious secondary structure that a researcher needs to preserve through careful folding conditions.

That simplicity has practical consequences. A four-residue peptide should be straightforward to synthesise by standard solid-phase peptide synthesis, straightforward to purify by reverse-phase HPLC, and straightforward to confirm by mass spectrometry. In other words, Epitalon is not a molecule where a supplier can credibly claim that documentation is impossible because the chemistry is too difficult. If a vendor cannot provide a batch-specific certificate of analysis showing identity and purity, the problem is not the peptide. The problem is the vendor.

The short sequence also shapes how researchers think about mechanism. Epitalon is too small to resemble the classical receptor agonists in the incretin category. It is not a GLP-1 receptor agonist, not a ghrelin mimetic, not a growth-hormone-releasing hormone analogue, and not a thymosin fragment. Much of the published mechanistic discussion instead focuses on possible nuclear, epigenetic, antioxidant, and gene-expression effects. Some of that discussion is plausible, especially given the documented ability of short peptides to interact with DNA or regulatory proteins in certain systems. Some of it remains speculative.

The name itself can cause confusion. Epitalon, Epithalon, Epithalone, and AEDG can all refer to the same tetrapeptide. Epithalamin, by contrast, is a pineal-gland polypeptide extract rather than the isolated tetrapeptide. Many older papers discuss epithalamin and Epithalon together because the tetrapeptide was developed as a defined synthetic analogue intended to capture part of the biological signal associated with the extract. Researchers building a reference library should keep these terms separate. A finding in an extract is not automatically a finding in AEDG.

The research lineage: pineal peptides, ageing, and the Khavinson corpus#

The Epitalon literature begins in a research tradition that treated the pineal gland as a central ageing-regulatory organ. That was not an eccentric starting point. The pineal gland produces melatonin, melatonin rhythms change with age, and circadian disruption interacts with endocrine, immune, metabolic, and reproductive physiology. The leap made by the Russian peptide-bioregulator programme was to ask whether short peptides derived from tissue extracts could modify gene expression and restore aspects of age-altered tissue function.

Epithalamin, the pineal extract, came first. Animal studies from the late twentieth century examined lifespan, tumour incidence, melatonin rhythms, immune parameters, and reproductive ageing. A frequently cited PubMed-indexed example is the 1992 report on pineal peptide preparation effects on lifespan and melatonin in old rats (Anisimov et al., 1992). Reviews such as Khavinson, 2002 summarised this broader pineal-peptide ageing programme, including claims around melatonin production and lifespan effects in experimental animals.

Epitalon was developed as a defined, synthetic tetrapeptide within that programme. The appeal is obvious: an extract is chemically heterogeneous, while a tetrapeptide is specific, manufacturable, and testable. The problem is equally obvious: when the field moved from extract to defined peptide, it inherited a broad set of claims that needed to be re-established for the smaller molecule.

The strongest reason Epitalon remained in the research conversation is the telomerase claim. In 2003, Khavinson and colleagues reported that Epithalon induced telomerase activity and telomere elongation in human somatic cells (PubMed: 12937682). That paper is short, widely cited in longevity circles, and important because it connects AEDG to a mechanism that ageing researchers already take seriously. Telomeres shorten during replicative ageing in many somatic cells, telomerase can maintain telomere length, and telomere biology has a substantial independent literature.

But the leap from a cell-culture telomerase signal to a practical anti-ageing intervention is large. Telomerase is not intrinsically good or bad; it is context-dependent. Telomerase activation can support cell replicative capacity, but telomerase biology also intersects with cancer biology, stem-cell maintenance, tissue turnover, and genomic stability. Any article that says "Epitalon activates telomerase, therefore it reverses ageing" is compressing a complex field into a slogan.

A useful way to read the Khavinson corpus is as hypothesis-generating rather than definitive. It offers repeated signals across cell and animal models, some mechanistic proposals, and an unusually persistent research programme. It does not offer the kind of multi-centre, independent clinical evidence that would justify broad claims about human anti-ageing outcomes.

Telomerase and telomere claims: what the evidence can and cannot say#

Telomeres are repetitive DNA-protein structures at chromosome ends. They protect coding DNA from loss during replication and help prevent chromosome-end recognition as DNA damage. In many somatic cells, telomeres shorten with repeated division because DNA polymerase cannot fully replicate chromosome ends. Telomerase, a ribonucleoprotein enzyme complex, can extend telomeres by adding repeat sequences. The catalytic protein component, hTERT in humans, is a central regulatory node.

The Epitalon telomerase claim is built on the observation that AEDG may increase telomerase activity or telomere length in cell systems. The 2003 Khavinson paper is the canonical starting point. More recently, a 2025 Biogerontology paper reported that Epitalon increased telomere length in human cell lines through hTERT upregulation or alternative lengthening mechanisms (PubMed: 40908429). A 2025 open-access review in Biomolecules summarised the broader Epitalon literature and placed telomerase activity among several proposed mechanisms (Overview of Epitalon).

Those papers are worth reading. They do not make the compound clinically settled. Cell-line experiments answer cell-line questions: whether a molecule changes an assay under defined conditions, at defined concentrations, in defined cells. They do not answer whether a lyophilised research vial produces meaningful organism-level effects in a complex mammalian model, much less whether a human outcome follows. Telomere assays also have technical variability. Measurement method, passage number, cell stress, baseline telomere length, and culture conditions can all change interpretation.

For researchers, the cleanest reading is this: Epitalon has enough telomere-related signal to justify mechanistic investigation. It does not have enough independent, replicated, clinical evidence to justify anti-ageing certainty.

The cancer-biology caveat deserves explicit mention. Telomerase is active in many cancers because malignant cells need replicative immortality. That does not mean every telomerase-modulating compound is carcinogenic, and it does not mean Epitalon has demonstrated such a signal. It does mean that simplistic telomerase enthusiasm is scientifically careless. A well-designed Epitalon study should treat proliferative markers, genomic stability, and tissue context as part of the question rather than as inconvenient footnotes.

Pineal, melatonin, and circadian hypotheses#

The pineal connection is the second major pillar of Epitalon research. Ageing is associated with changes in circadian amplitude and melatonin secretion, and pineal peptides were originally studied partly because they appeared to influence those rhythms in animals. Melatonin itself is not merely a sleep hormone; it is an endocrine timing signal with antioxidant, immune, reproductive, and metabolic interactions. That makes pineal peptide claims biologically plausible enough to investigate.

The older epithalamin literature includes animal data on pineal and serum melatonin changes. Some studies reported improved circadian rhythmicity or endocrine markers in aged animals. A 2012 review discussed melatonin and pineal gland peptides in relation to reproductive-cycle impairment in rats (PubMed: 23237594). The broader claim is that pineal peptide signalling may partially correct age-altered neuroendocrine rhythms.

For Epitalon specifically, researchers should separate three layers. The first is the pineal extract layer: heterogeneous preparations influencing melatonin-related endpoints. The second is the AEDG layer: defined tetrapeptide studies that may or may not replicate extract effects. The third is the commercial extrapolation layer: claims that a vial of AEDG will restore sleep, hormones, or ageing trajectories in humans. The first two belong in a literature review. The third requires evidence that does not currently exist at the standard implied by the claims.

Circadian endpoints are also easy to confound. Light exposure, feeding time, animal housing, stress, age, sex, and sampling time can all shift melatonin or clock-gene readouts. If a lab is studying Epitalon in a circadian model, the protocol needs unusually disciplined sampling windows. A poorly timed melatonin assay can look like a peptide effect when it is really a clock artefact.

Antioxidant and gene-expression mechanisms#

A third strand of the literature frames Epitalon as an antioxidant or gene-expression-modulating peptide. The 2025 overview article summarises proposed geroprotective, neuroendocrine, antioxidant, and metabolic effects. Other open-access work has reported AEDG effects on gene expression and protein synthesis in human stem-cell models, including neuronal differentiation-related genes (AEDG and gene expression).

Short peptides can influence gene expression through several possible routes. They may interact with DNA grooves, bind histones or transcriptional regulators, alter cell stress pathways, or change upstream signalling that secondarily shifts transcription. The Russian peptide-bioregulator model often emphasises direct peptide-DNA or peptide-chromatin interactions. Western molecular pharmacology has been slower to adopt that model, partly because the binding specificity and in-cell target validation are difficult to establish.

This is where Epitalon research becomes both interesting and fragile. If AEDG truly regulates specific gene-expression programmes at low concentrations, it would be a remarkable example of short-peptide signalling. If the observed changes are indirect stress responses, assay artefacts, or cell-culture-specific phenomena, the interpretation changes substantially. Researchers should look for studies that include dose-response curves, appropriate scrambled-peptide controls, independent replication, and mechanistic blockade rather than relying on before-and-after gene lists alone.

Antioxidant claims require the same caution. Reductions in oxidative-stress markers can be meaningful, but they can also reflect altered cell viability, changed metabolic rate, or assay interference. A robust antioxidant study should include multiple orthogonal readouts: reactive oxygen species assays, lipid peroxidation markers, mitochondrial function, antioxidant enzyme expression, and viability controls. Single-marker claims are weak.

How Epitalon differs from NAD+, SS-31, Humanin, and other longevity compounds#

The anti-ageing category is crowded, and crowded categories invite lazy grouping. Epitalon is often discussed alongside NAD+, SS-31, Humanin, GDF-11, FOXO4-DRI, and mitochondrial-derived peptides. The shared label is "longevity," but the underlying biology is not shared in a simple way.

NAD+ is a coenzyme central to redox biology and substrate availability for sirtuins, PARPs, and CD38. Research questions around NAD+ typically involve cellular energy state, DNA repair signalling, inflammatory metabolism, and age-associated decline in NAD+ pools. Epitalon is not a coenzyme and does not substitute for NAD+ biology.

SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide designed to interact with cardiolipin and improve mitochondrial inner-membrane function in certain disease models. Its research literature sits in bioenergetics, oxidative stress, mitochondrial myopathy, ophthalmology, and cardiac models. Epitalon's telomerase and pineal-circadian story is mechanistically distinct.

Humanin is a mitochondrial-derived peptide associated with cytoprotective signalling, metabolic regulation, and stress resistance. It is longer than Epitalon and engages receptor-mediated pathways that are still being mapped. Again, the overlap is thematic rather than mechanistic.

A good Canadian research programme can compare these compounds, but it should not conflate them. If the study question is telomerase expression, Epitalon may be relevant. If the question is mitochondrial membrane potential under oxidative stress, SS-31 may be the more direct tool. If the question is NAD+ depletion under metabolic stress, NAD+ precursors or NAD+ itself belong in the design. Category labels should follow mechanisms, not marketing shelves.

What the main endpoints should look like#

A well-built Epitalon study should define its endpoint before the vial is opened. The compound's reputation is broad, but broad reputation is not a research design. The endpoint determines the assay, the sampling schedule, the controls, and the kind of supplier documentation that matters most.

For telomerase work, the common endpoint is telomerase activity, often measured by a telomeric repeat amplification protocol or a related assay. That assay should be paired with hTERT expression, cell viability, and population-doubling records. A single activity readout can be misleading if the peptide changes cell survival or stress state. If telomere length is the endpoint, the study needs longer observation and an explicit measurement method such as qPCR-based relative telomere length, terminal restriction fragment analysis, or a validated flow-FISH approach. Each method has trade-offs. qPCR is scalable but variable; terminal restriction fragment analysis is slower but historically robust; flow-FISH can be powerful when cell populations are clearly defined.

For circadian or pineal-linked work, timing discipline is everything. Melatonin, clock genes, corticosterone or cortisol analogues, body temperature, and activity rhythms all move across the day. Sampling a treated group at one zeitgeber time and a control group at another is enough to destroy interpretability. Researchers should pre-register sampling windows in the protocol, keep light exposure consistent, and report feeding and handling times. In animal work, age and sex should be considered design variables rather than background details.

For oxidative-stress work, the strongest designs use multiple readouts. A reactive oxygen species assay alone is not enough. Better designs pair ROS readouts with mitochondrial membrane potential, lipid peroxidation markers, antioxidant enzyme expression, DNA-damage markers, and viability. If Epitalon appears to reduce oxidative signal while also reducing metabolic rate or cell number, the interpretation is not straightforward. If it reduces oxidative markers while preserving viability and function after a defined insult, the claim becomes more interesting.

For gene-expression work, scrambled-peptide controls are especially important. AEDG is four amino acids long, and generic peptide effects are possible. A scrambled sequence does not answer every mechanistic question, but it helps separate sequence-specific biology from amino-acid exposure, osmotic shifts, or handling artefacts. Follow-up protein-level confirmation is also necessary. mRNA changes that never appear as protein changes may still be meaningful, but they should not be written as if they are completed pathway activation.

Analytical verification: why Epitalon should be easy to check#

Epitalon is not an analytical black box. Its small size makes identity confirmation simpler than for many larger peptides. That is why quality documentation should be held to a high standard. A supplier that hides behind vague "third-party tested" language without a lot-matched document is offering less than the molecule allows.

HPLC purity is the first layer. A credible chromatogram should show the main AEDG peak and quantify detectable impurities under the stated method. Purity above 98 percent is commonly advertised in the market, but the number is only meaningful if attached to a batch, a method, and a chromatogram. Researchers should be wary of copied COAs where every batch shows the same purity to two decimal places. Real analytical data varies.

Mass spectrometry is the second layer. AEDG has a known molecular mass, so identity confirmation should be routine. The mass spectrum does not need to be exotic; it needs to show that the product in the vial corresponds to the expected tetrapeptide rather than a deletion sequence, salt form confusion, or unrelated short peptide. For Epitalon, failure to provide MS confirmation is a red flag.

Water content and residual solvent data are useful but not always present on retail research-peptide COAs. They matter when the protocol depends on exact mass concentration or when long-term storage stability is important. A vial that contains more residual moisture than expected can degrade faster even when the labelled peptide mass is nominally correct. For most exploratory bench work, HPLC and MS are the non-negotiables; water content is a quality-marker upgrade.

Independent verification remains the gold standard when a study is important enough. Sending a retained sample to an analytical lab for HPLC-MS confirmation adds cost, but it prevents a common failure mode in peptide research: interpreting biology from a vial whose contents were never independently verified. The shorter and cheaper the peptide, the less excuse there is for skipping identity confirmation in serious work.

Limits, risks, and common overstatements#

The biggest Epitalon overstatement is that telomerase activation equals safe rejuvenation. It does not. Telomere biology is central to ageing research, but it is also central to cancer biology, stem-cell biology, and replicative control. A compound that shifts telomerase-linked markers deserves careful study precisely because the pathway is important. Importance is not the same as uncomplicated benefit.

The second overstatement is that animal lifespan findings from pineal extracts prove the effect of the synthetic tetrapeptide. Extracts and defined peptides are different research materials. Epithalamin studies are part of the history, but they cannot be pasted directly onto AEDG. When a secondary source blurs epithalamin and Epitalon without explaining the distinction, treat the rest of the source cautiously.

The third overstatement is that Russian clinical or gerontology experience settles the question for modern Canadian researchers. Some of that literature is worth reading, but the standards of reporting, randomisation, blinding, endpoint selection, and independent replication vary. A careful review can include those findings while still acknowledging that they do not replace contemporary controlled trials.

The fourth overstatement is that because Epitalon is short, it is automatically stable and problem-free. Short peptides are often easier to handle, but they can still degrade, adsorb to surfaces, arrive underfilled, or be mislabelled. Small does not mean exempt from documentation.

Finally, researchers should avoid claims about treating insomnia, reversing ageing, preventing cancer, restoring fertility, or extending human lifespan. Those are therapeutic claims. They are not supported to the standard required for human-use recommendations, and they are not appropriate for an RUO editorial funnel. Epitalon can be discussed seriously without pretending it is clinically proven.

Canadian regulatory and compliance context#

In Canada, Epitalon is not an authorised anti-ageing medication. It does not have a Health Canada Drug Identification Number for therapeutic use, and it should not be represented as a treatment for ageing, insomnia, immune decline, cancer prevention, neurodegeneration, or endocrine dysfunction. Research-use-only material is not the same thing as pharmacy-grade medicine.

That distinction matters because Epitalon sits in a category where consumer demand and research interest overlap uncomfortably. A Canadian supplier can sell lyophilised research material labelled for laboratory use. That does not convert the compound into a human-use product, and it does not shift responsibility away from the purchaser. Researchers remain responsible for lawful use, institutional approvals where applicable, documentation, storage, waste handling, and protocol design.

The Canadian research peptide buyer guide covers this broader landscape in more detail. The key point for Epitalon is simple: treat the vial as a research chemical, not as a wellness product. A supplier that markets Epitalon with personal anti-ageing promises, before-and-after claims, or casual dosing language is telling you something about its compliance culture. That signal should matter.

Northern Compound's editorial standard is deliberately conservative here. The evidence base is interesting enough for a serious article. It is not strong enough for therapeutic advice. Readers should verify current regulations, supplier documentation, and institutional requirements before designing work around any research peptide.

Sourcing Epitalon in Canada: COA, identity, purity, and storage#

Because Epitalon is short and simple, quality control should be direct. A credible batch should come with HPLC purity and mass spectrometry identity confirmation. HPLC answers whether the major peak corresponds to a high-purity product relative to detectable impurities. Mass spectrometry answers whether the molecular mass matches AEDG. Neither test alone is sufficient. A pure wrong peptide is still wrong, and a correct peptide with substantial impurities is still a poor research input.

The certificate of analysis should be batch-specific. Generic COAs are common in the research peptide market and should be treated as weak evidence. A lot number on the vial should match a lot number on the document. The document should list method, date, measured purity, and identity result. Ideally, the supplier also provides chromatogram and mass spectrum images rather than a one-line purity claim. For a molecule as small as Epitalon, this is not an unreasonable expectation.

Researchers evaluating Epitalon should also check handling details. Lyophilised AEDG is more robust than many larger peptides, but storage still matters. Sealed vials should be kept dry, protected from heat, and refrigerated or frozen according to supplier guidance. Reconstituted solution is more vulnerable to microbial contamination and repeated temperature cycling. If a protocol requires repeated sampling from one vial, bacteriostatic water may be used in research contexts where compatible with the assay; if a protocol requires immediate analytical use, sterile water or buffer may be appropriate depending on downstream methods. The broader mechanics are covered in How to Reconstitute Peptides.

A practical Epitalon supplier checklist looks like this:

• Batch-specific COA with lot number matching the vial.
• HPLC purity with a real chromatogram or detailed method summary.
• Mass spectrometry identity confirmation near the expected AEDG mass.
• Clear lyophilised and reconstituted storage guidance.
• Research-use-only labelling and no human-use claims.
• Domestic shipping practices that avoid prolonged heat exposure.
• Responsive support when a researcher asks for documentation.

Lynx Labs is the supplier Northern Compound currently points researchers toward for domestic sourcing because the product catalogue includes Epitalon in the anti-ageing category and the store-level documentation model is consistent with our COA-first standard. That is a sourcing assessment, not a medical endorsement. Researchers should still verify the current batch documents before ordering or opening a vial.

Study-design considerations for Epitalon research#

Epitalon studies can go wrong in predictable ways. The first failure mode is endpoint sprawl. Because the compound is discussed in relation to telomeres, melatonin, antioxidant biology, immune function, lifespan, and gene expression, it is tempting to measure everything. That rarely produces interpretable data. A better design starts with one primary question: telomerase activity in a defined cell type, clock-gene expression under a circadian sampling schedule, oxidative-stress response after a specified insult, or tissue repair in a model where the mechanism is plausible.

The second failure mode is weak controls. A scrambled tetrapeptide control is valuable because it helps distinguish sequence-specific effects from generic amino-acid or peptide effects. Vehicle controls are necessary. Passage-matched cell controls are necessary for telomere experiments. Positive controls should be selected carefully; for telomerase assays, a known telomerase-positive cell line may serve as an assay control, but it does not substitute for a biological comparator.

The third failure mode is overinterpreting short time windows. Telomere length does not meaningfully change in every system over short exposure intervals, and cell stress can transiently alter telomerase readouts without producing durable telomere maintenance. If the endpoint is telomerase activity, a short assay may be reasonable. If the endpoint is telomere length, longer observation and proper population-doubling records are essential.

The fourth failure mode is ignoring sex, age, and circadian timing in animal models. Pineal and melatonin biology is deeply timing-sensitive. Sampling at the wrong phase can flatten a real effect or manufacture a false one. Animal age matters because many claims relate specifically to age-associated decline. A young-animal model may not test the hypothesis being asserted.

Finally, researchers should avoid importing human wellness assumptions into preclinical design. Epitalon research should be framed around mechanisms and measurable endpoints, not around personal anti-ageing narratives.

A practical decision framework#

Epitalon is worth considering when the research question is explicitly connected to one of the compound's plausible mechanisms. It is less appropriate when the study simply needs a fashionable longevity peptide.

Choose Epitalon as a candidate research tool when:

• The primary endpoint involves telomerase activity, hTERT expression, telomere maintenance, or related chromosomal ageing markers.
• The study is examining pineal, melatonin, circadian, or neuroendocrine ageing models with disciplined sampling.
• The protocol can include appropriate controls, including scrambled peptide or sequence-specific comparators.
• The lab can verify identity and purity through supplier COA review or independent analytical testing.
• The write-up will distinguish cell, animal, and human evidence rather than blending them.

Deprioritise Epitalon when:

• The outcome of interest is mitochondrial membrane function, where SS-31 may be more direct.
• The outcome is NAD+ pool restoration or sirtuin substrate availability, where NAD+ biology is the actual target.
• The study requires a compound with a large, independently replicated clinical evidence base.
• The project cannot tolerate ambiguity around mechanism.
• The supplier provides no lot-matched analytical documentation.

This framework is intentionally conservative. The compound's appeal is not that it is proven to be a universal anti-ageing intervention. Its appeal is that it touches several important ageing-biology hypotheses in a small, testable molecule.

Frequently asked questions#

References and further reading#

• Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003. PubMed
• Anisimov VN et al. Effect of pineal peptide preparation (epithalamin) on life span and pineal and serum melatonin level in old rats. 1992. PubMed
• Khavinson VK. Peptides and ageing. 2002. PubMed
• Vinogradova IA et al. Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats. Current Aging Science. 2012. PubMed
• Overview of Epitalon—highly bioactive pineal tetrapeptide with geroprotective and neuroendocrine research relevance. Biomolecules. 2025. PMC
• AEDG peptide (Epitalon) stimulates gene expression and protein synthesis in human stem-cell models. PMC
• Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. PubMed